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24 Qualitative study on parental views on the most acceptable way
to be told their child has a probable diagnosis for cystic ﬁbrosis
following neonatal screening
J. Collinson1, A. Crutchley1. 1Northampton General Hospital, Child Health,
Northampton, United Kingdom
Objectives: This study reviews parental views on how they were informed of the
probable CF diagnosis, following neonatal screening, and explores which method
parent’s found most acceptable.
Methods: Retrospective questionnaires were used to ﬁnd parents’ views on how
they were told that their child had a probable diagnosis of CF, who told them
initially, were they told at home or by the GP followed by hospital, how acceptable
was the mode of information sharing?
Results: 40 parents of children with CF were studied. Most parents (9 out of 12)
who had been informed by their GP recall receiving inaccurate information about
the condition. All parents (28 out of 28) who had received a home visit to be told
about the CF diagnosis felt that the information received had been accurate and
found it easier to accept.
Conclusion: Our qualitative study conﬁrms that parents who were given accurate
information by CF professionals during a home visit found this an acceptable means
of being informed of the probable diagnosis of CF. Parents reported less negative
recollections of that time than parents who were informed by their GP and met CF
professionals in hospital. We consider that this is a superior method of sharing the
information about the diagnosis of CF.
25 Cystic ﬁbrosis (CF) prevalence derived from CF newborn
screening (CFNBS) in the Czech Republic: comparison of previous
epidemiological and current CFNBS-based disease prevalence data
V. Krulisˇova´1, A. Holubova´1, T. Piska´cˇkova´1, M. Balasˇcˇakova´1, V. Skalicka´2,
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Czech Republic; 3University Hospital Brno, Masaryk University, Faculty of Medicine,
Department of Medical Genetics and Biology, Brno, Czech Republic; 4University
Hospital Brno, Masaryk University, Faculty of Medicine, Department of Clinical
Biochemistry, Brno, Czech Republic; 5Charles University − 3rd Faculty of Medicine
and University Hospital Kra´lovske´ Vinohrady, Department of Pediatrics, Prague,
Czech Republic
Objectives: More than 30 years old epidemiological estimates at birth CF prevalence
are approximately 1 in 3,000 in the Czech (CZ) Republic. Since the introduction of
the CZ CFNBS in 10/2009 we have documented substantially lower disease prevalence
of 1 in 6,330. Based on the outcomes of the nationwide IRT/DNA/IRT protocol we
assessed potential sources of the bias.
Methods: Data from the CZ Institute of Health Information and Statistics and CZ CF
registry were utilized. Infants with equivocal diagnoses of CF were excluded.
Results: A total of 367,114 newborns underwent CFNBS (8/2009−12/2012). Within
this period 58 patients were diagnosed (of which 52 via IRT/DNA/IRT) with classic
CF leading to prevalence 1 in 6,330 in the CZ Republic.
Conclusion: The current prevalence based on CFNBS in the CZ Republic is markedly
lower than the original data. This could be due to
a. possible false negativity of CFNBS;
b. impact of prenatal diagnosis and pre-implantation genetic diagnosis (PGD) and
c. increasing birth-rate of non-European immigrants.
Within the study period 15 pregnancies were terminated due to CF in the fetus resulting
in modiﬁed prevalence of 1 in 5,029. Considering the existence of PGD for CF
(statistics are unavailable) we can presume slightly higher population risk for CF.
The historical higher prevalence could be due to regional bias (1 in 2,700 in Central
Bohemia, 1 in 3,300 in the former Czechoslovakia) and/or smaller numbers. Finally,
current CF prevalence data are in accordance with those from other European CFNBS
programs.
Supported by CZ.2.16/3.1.00/24022OPPK and 00064203 and PRVOUK P31.
26 Risk factors for poor outcomes in cystic ﬁbrosis newborns
diagnosed by neonatal screening in Italy: years 2009−2011
T. Repetto1, R. Buzzetti2, N. Cirilli3, R. Padoan4, P. Piccinini5, I. Vecchini6,
L. Zavataro6. 1Meyer Children’s University Hospital, Health Science Department,
Florence, Italy; 2Italian Cystic Fibrosis Research Foundation, Verona, Italy;
3Salesi Children Hospital, Mother–Child Department, Ancona, Italy; 4Children
Hospital, Brescia, Italy; 5Freelance Statistician, Bergamo, Italy; 6Meyer Children
Hospital, Florence, Italy
Objectives: To identify risk factors associated with poor clinical outcomes in CF
diagnosed by NBS in Italy.
Methods: Our survey include CF infants born and diagnosed in the years 2009–
2010–2011 recruited in the 16 Italian CF care Centres of Regions where CFNBS is
performed. They were evaluated according to: gender, ethnicity, genotype, pancreas
status, meconium ileus (MI), age at diagnosis and longitudinal outcomes: weight,
height, Ps infection, pulmonary exacerbations at age of 6mo and 1−2−3 y.
This is a longitudinal cohort and nested case–control study: cases were infants
presenting at least ONE of the following variables (primary outcome): stunting,
wasting, Ps chronic infection at age of 1 y; controls were infants matched for age
not presenting the primary outcome.
Results:We have collected data from 399 children. The total rate of cases was 20%:
19.8% among patients with classical CF diagnosed by screening, 1.8% among
“equivocal” CF, 40% among MI, 33% among CF diagnosed by symptoms and
40% among CFNBS false negatives.
In order to identify risks factors associated to adverse outcomes we considered 34
cases and 162 controls. Not statistically signiﬁcant associations with: CF Centre,
gender, genotype, ethnicity, nationality, occupation of parents, age at diagnosis,
age of onset of physiotherapy was found. Signiﬁcant association was found with
pancreatic insufﬁciency (OR= 3.065, 95%CI 1.02–9.18, P< 0.05).
Subjects presenting the primary outcome have length or weight at age of 2 and 3 y
signiﬁcantly lower than controls.
Conclusion: Clinicians should pay close attention to nutritional status of infants
during the ﬁrst year of life.
27 Infants with an equivocal diagnosis at the Oslo CF centre following
newborn screening for CF in Norway
E. Bakkeheim1, O.-T. Storrøsten1, E. Lundman2, H.J. Gaup2, R.D. Pettersen2.
1Oslo University Hospital, Norwegian Resource Centre for Cystic Fibrosis,
Department of Paediatrics, Oslo, Norway; 2Oslo University Hospital, The National
Neonatal Screening Unit, Women and Children’s Division, Oslo, Norway
Objectives: Norway started newborn screening (NBS) for CF on March 1st 2012
with an IRT/DNA protocol. Infants with a positive NBS for CF are deﬁned as
either having signiﬁcantly increased immunoreactive trypsinogen (IRT) (cut off
value 99.5 p) and two identiﬁed CFTR mutations or markedly elevated IRT levels.
The aim of the study was to assess the frequency of an equivocal CF diagnosis
after positive NBS with corresponding CFTR mutations and to assess whether
sweat chloride (SC) levels and pancreatic status could clarify the diagnosis.
Methods: NBS positive infants with an equivocal diagnosis were registered from
March 1st 2012 until December 31st 2013. SC was measured initially and after six
months age. Pancreatic status was determined by quantifying fecal elastase.
Results: 22 infants were followed up at the Oslo CF centre in this period, and 10
infants (45%) were heterozygous to indeterminate CFTR mutations (R117 H with
different poly T tract status). At follow up two infants (n1 and n7) with initial
indeterminate SC levels had positive SC levels (60mmol/L) (Table 1).
Table 1.
Infant Poly T tract
status
Initial SC
(mmol/L)
Follow up SC
(mmol/L)
Fecal elastase
(mg/g)
n1 5T/9T 53 and 54 62 442
n7 7T/9T 37 and 40 62 >500
Eight infants had negative (<30mmol/L) or indeterminate (30−59mmol/L) SC
levels. Fecal elastase was normal in all infants.
Conclusion: At the Oslo CF centre the rate of NBS positive individuals with
an initial equivocal diagnosis was 45%. All of these had at least one R117H
CFTR mutation and were pancreatic sufﬁcient. The SC levels could not clarify
the diagnosis in all individuals. SC levels in two infants turned positive in the
follow up.
